Saflutan (tafluprost) is an analogue of prostaglandin F2α.1 Like other drugs of this class, tafluprost reduces intraocular pressure by increasing the outflow of aqueous humour.
A randomised, double-blind trial compared the efficacy of tafluprost (15 micrograms per ml once daily) and latanoprost (50 micrograms per ml once daily) in 533 patients with open angle glaucoma or ocular hypertension.2 Analysis of variance indicated that the mean reduction in diurnal intraocular pressure produced by tafluprost after 24 months had reached the threshold of non-inferiority to latanoprost.
Tafluprost (15 micrograms per ml once daily) was superior to vehicle in reducing intraocular pressure as an adjunctive treatment to timolol (5 milligram per ml twice daily) in a randomised, double-blind 12-week trial in 185 patients.3
- Saflutan Summary of Product Characteristics. June 2008.
- Uusitalo H, Pillunat L et al. Phase III, 24-month study investigating the efficacy and safety of tafluprost vs latanoprost in patients with open-angle glaucoma or ocular hypertension. Acta Ophthalmol 2008: 86; 529.
- Egorov E, Ropo A et al. Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma. Eur J Ophthalmol 2009: 19; 214-22.
Further information: MSD